Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eczema

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.

Investors Business Daily

Revolutionary eczema treatment ‘could end years of suffering’ for patients

Scientists have secured over £475,000 for clinical research on the "groundbreaking" new technology

The Independent UK

New eczema tool could benefit millions of patients

IN FULL

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

New technology could ‘revolutionise’ eczema treatment for patients with skin condition

Experts say the new tool could end ‘years of suffering for millions of patients across the UK’

The Independent UK

University hails £475,000 fund into ‘groundbreaking’ eczema technology

Heriot-Watt said the device could help those with psoriasis and ‘revolutionise how eczema is diagnosed and treated’.

Evening Standard

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'

Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.

Investors Business Daily

8 best hypochlorous acid sprays to cleanse and soothe, tested by a beauty expert

Bye bye inflammation, hello clean, soothed skin

The Independent UK

If you get itchy from detergent residue, you need to try Clean People Laundry Sheets – people with allergies swear by them

They would be a lifesaver for my partner with eczema

Homes & Gardens

Amanda Seyfried shares her go-to routine for eczema – and the unexpected product she calls her 'secret weapon'

This one makeup buy changed her look for good…

Woman & Home

More than Skin Deep: Exploring Rejuvaskin's Mission to Redefine Skin Health

For Chris Christenberry, CEO of Rejuvaskin, skin health goes beyond skincare buzzwords and marketing trends, but is rooted in medical necessity.

International Business Times

The childhood experience that may lower your risk of asthma and eczema

Evidence suggests that early exposure to family members, food, germs, dust, dirt, pollen, and pets shapes our immune response

The Independent UK

If you have a pet as a kid, does this lower your risk of asthma and eczema?

As the number of people with allergies grows worldwide, scientists are trying to work out precisely how and why these conditions – such as asthma and eczema – develop.

The Conversation

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.

MarketBeat

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

Investors Business Daily

Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema treatment.

The Independent UK

How having a pet dog can alter some children’s immune systems

IN FULL

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Study shows what a pet dog can do to save your child’s skin from eczema

Academics said that having a pet dog in early life could have a ‘protective effect’

Evening Standard

A pet dog could potentially prevent eczema in at-risk children – study

Researchers said the protective effect of owning a pet dog may ‘occur at a molecular level’.

The Independent UK

There are many causes of dandruff – but how do you prevent it?

What looks like dandruff is often caused with not washing your hair regularly enough

Evening Standard

Best itchy skin treatment: Scalp to shins relief with expert tips

Itching to know what’s causing that scratch? Learn how hydration, barrier repair, and ingredient choices can bring lasting comfort

The Independent UK

Young woman ‘would do anything to have eczema again’ after steroid withdrawal

Bethany Gamble used steroid creams to treat her eczema from the age of two - then they stopped working

The Guardian - UK

Is it true that … showering every day is bad for your skin?

Does the length of time you stand in the water make a difference? And what about the temperature?

The Conversation

First Nations Australians are more likely to present to hospital with asthma and allergies – new research

Australia is often called the allergy capital of the world. Allergic diseases – such as allergic asthma, hay fever, eczema and food allergies – affect almost one in five people. And this figure is expected to rise in the years to come.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

HeriotWatt University

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.